Loss of heterozygosity on chromosome 1 and 9 and hormone receptor analysis of metastatic malignant melanoma presenting in breast

International Journal of Surgical Pathology

Volumn 13, Issue 1, 2005, Pages 9-18

  Beaty, Michael W ^a   Quezado, Martha ^a   Sobel, Mark E ^a   Duray, Paul ^a   Merino, Maria J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast; Chromosome 9q22.3; Hormone receptors; Loss of heterozygosity; Melanoma; Metastasis; p15 gene

Indexed keywords

ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CARCINOGENESIS; CHROMOSOME 1; CHROMOSOME 9P; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA EXTRACTION; FEMALE; GENETIC MARKER; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HORMONE DETERMINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; METASTASIS; MICRODISSECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 13544263570     PISSN: 10668969     EISSN: None     Source Type: Journal    
DOI: 10.1177/106689690501300102     Document Type: Article

References (41)

1. Jayalakshmi S, Chander S, Prasad RR, Saxena AK, Sharma MC, Rath GK. Malignant melanoma presenting as bilateral breast masses. Australas Radiol 41:38-40, 1997
2. Vergier B, Trojani M, De Mascarel I, Coindre JM, Le Truet A. Metastases to the breast: Differential diagnosis from primary breast carcinoma. J Surg Oncol 48:112-116, 1991
3. Pressman PI. Malignant melanoma and the breast. Cancer 31:784-788, 1973
4. Chaignaud B, Hall TJ, Powers C, et al. Diagnosis and natural history of extramammary tumors metastatic to the breast. J Am Coll Surg 179:49-53, 1994
5. Reid D, Nimbkar N. Melanoma metastatic to breast. Mil Med 156:367-368, 1991
6. Stat bite: Incidence of and mortality from melanoma of the skin, 1975-2000. J Natl Cancer Inst 95:933, 2003
7. Arora R, Robinson WA. Breast metastases from malignant melanoma. J Surg Oncol 50:27-29, 1992
8. Donegan WL, Spratt JS. Metastatic neoplasms to the breast from other primary cancers. In Donegan WL, Spratt JS (eds): Cancer of the breast, 3rd ed. WB Sanders, Philadelphia, p. 644, 1988
9. Jochimsen PR, Brown RC. Metastatic melanoma in the breast masquerading as fibroadenoma. JAMA 236:2779-2780, 1976
10. Miller JG, Mac Neil S. Gender and cutaneous melanoma. Br J Dermatol 136:657-665, 1997
11. Miller JG, Gee J, Price A, Garbie C, Wagner M, Mac Neil S. Investigation of oestrogen receptors, sex steroids and soluble adhesion molecules in the progression of malignant melanoma. Mel Res 7:197-208, 1997
12. Grin CM, Driscoll MS, Grant-Kels JM. The relationship of pregnancy, hormones, and melanoma. Semin Cutan Med Surg 17:161-171, 1998
13. Smith MA, Fine JA, Barnhill RL, Berwick M. Hormonal and reproductive influences and risk of melanoma in women. Int J Epidemiol 27:751-757, 1998
14. Duncan LM, Travers RL, Koerner FC, Mihm MC, Sober AJ. Estrogen and progesterone receptor analysis in pregnancy-associated melanoma: Absence of immunohistochemically detectable hormone receptors. Hum Pathol 25:36-41, 1994
15. Cohen C, De Rose PB, Campbell WG, Schlosnagle DC, Sgoutas D. Estrogen receptor status in malignant melanoma. Am J Dermatopathol 12:562-564, 1990
16. Piantelli M, Maggiano N, Ricc R, et al. Tamoxifen and quercetin interact with type II estrogen binding sites and inhibit the growth of melanoma cells. J Invest Dermatol 105:248-253, 1995
17. Walker MJ, Ronan SG, Han MC, et al. Interrelationship between histopathologic characteristics of melanoma and estrogen receptor status. Cancer 68:184-188, 1991
18. Chin L, Merlino G, DePinto RA. Malignant melanoma: Modern black plague and genetic black box. Genes Dev 12:3467-3481, 1998
19. Nelson MA, Thompson FH, Emerson J, Aickin M, Adair L, Trent JM, Leong SP, Taetle R. Clinical implications of cytogenetic abnormalities in melanoma. Surg Clin North Am 76:1257-1271, 1998
20. Kraehn GM, Schatrl M, Peter RU. Human malignant melanoma: A genetic disease? Cancer 75: 1228-1237, 1995
21. Cannon-Albright LA, Goldgar DE, Neuhausen S, Gruis NA, Anderson DE, Lewis CM, et al. Localization of the 9p melanoma susceptibility locus (MLM) to a 2-cM region between D9S736 and D9S171. Genomics 23:265-268, 1994
22. Goldstein AM, Dracopoli NC, Engelstein M, Graser MC, Clark WH, Tucker MA. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet 54:489-496, 1994
23. Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlock DR, Titus-Ernstoff L, et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 89: 10557-10561, 1992
24. Holland EA, Beaton SC, Edwards BG, Kefford RF, Mann GJ. Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma. Onocgene 9:1361-1365, 1994
25. Walker GJ, Palmer JM, Walters MK, Nancarrow DJ, Parsons PG, Hayward NK. Refined localization of the melanoma (MLM) gene on chromosome 9p by analysis of allelic deletions. Oncogene 9:819-824, 1994
26. Piccinin S, Doglioni C, Maestro R, Vukosavljevic T, Gasparottto D, D'Orazi C, Bioicchi M. P16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int J Cancer 74:26-30, 1997
27. Robinson WA, Elefanty AG, Hersey P. Expression of the tumor suppressor genes p15 and p16 in malignant melanoma. Mel Res 6:285-289, 1996
28. Bale SJ, Dracopli NC, Tucker MA. Mapping the gene for hereditary malignant melanoma: Dysplastic nevus to chromosome 1p. N Engl J Med 320: 1367-1372, 1989
29. Dracopli NC, Harnette P, Bale SJ, Stanger BZ, Tucker MA, Housman DE, et al. Loss of alleles from the distant short arm of chromosome 1 occurs late in melanoma tumor progression. Proc Natl Acad Sci USA 86:4614-4618, 1989
30. Bale AE. The nevoid basal cell carcinoma syndrome: Genetics and mechanism of carcinogenesis. Cancer Invest 15:180-186, 1997
31. Goldstein AM, Stewart C, Bale AE, Dale SJ, Dean M. Localization of the gene for the nevoid basal cell carcinoma syndrome. Am J Hum Genet 54:765-773, 1994
32. Wicking C, Berkman J, Wainwright B, Chenevix-Trench G. Fine genetic mapping of the gene for nevoid basal cell carcinoma syndrome. Genomics 22:505-511, 1994
33. Holmberg E, Rozell BL, Toftgard R. Differential allele loss on chromosome 9q22.3 in human non-melanoma skin cancer. Br J Cancer 74:246-250, 1996
34. Morris DJ, Reis A. A YAC contig spanning the nevoid basal cell carcinoma syndrome, Fanconi anemia group C, and xeroderma pigmantosum group A loci on chromosome 9q. Genomics 23:23-29, 1994
35. Bogdan I, Xin H, Burg G, Boni R. Heterogeneity of allelic deletions within melanoma metastases. Melanoma Res 11:349-354, 2001
36. Marks R. An overview of skin cancers. Incidence and causation. Cancer 75(Suppl 2):607-612, 1995
37. Rifkin RM, Thomas MR, Mughal TI, Kaur JS, Krebs LU, Robinson WA. Malignant melanoma: Profile of an epidemic. West J Med 149:43-46, 1988
38. Shaw HM, McGovern VJ, Milton GW, et al. Malignant melanoma, influence of site of lesion and age of patient in the female, superiority in survival. Cancer 46:2731-2735, 1980
39. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440, 1994
40. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756, 1994
41. Greene MH. Genetics of cutaneous melanoma and nevi. Mayo Clin Proc 72:467-474, 1997